Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Mobilisation et Résultats Après Fermeture Veineuse (MOVE)

17 septembre 2026 mis à jour par: Cordis US Corp.

MOVE - Mobilisation et Résultats Après Fermeture VEineuse - Un Registre Prospectif des Résultats/Utilisations/Preuves en Conditions Réelles pour le Dispositif de Fermeture Vasculaire VEineux MYNX CONTROL™ 6F-12F

The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

The study is a single-arm, prospective, multi-center, observational, real-world registry of venous access site closures utilizing MYNX CONTROL™ VENOUS VCD 6F-12F following endovascular procedures. The study will enroll approximately 300 subjects in approximately 15 study sites in the United States.

Type d'étude

Observationnel

Inscription (Réel)

339

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • Los Angeles, California, États-Unis, 90048
        • Cedars Sinai Medical Center
      • Palo Alto, California, États-Unis, 94304
        • Stanford University School of Medicine
    • Colorado
      • Littleton, Colorado, États-Unis, 80210
        • South Denver Cardiology
    • Florida
      • Orlando, Florida, États-Unis, 32803
        • AdventHealth Orlando
    • Illinois
      • Glenview, Illinois, États-Unis, 60026
        • Glenbrook Hospital
    • Kansas
      • Overland Park, Kansas, États-Unis, 66211
        • KC Heart and Rhythm Institute
    • Kentucky
      • Lexington, Kentucky, États-Unis, 40503
        • Baptist Health Lexington
    • North Carolina
      • Raleigh, North Carolina, États-Unis, 27607
        • North Carolina Heart & Vascular Research, LLC
    • Washington
      • Bellevue, Washington, États-Unis, 98004
        • Overlake Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The study includes patients who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.

La description

Inclusion Criteria

  1. Able and willing to provide informed consent and to complete a follow-up visit at 14 ± 7 days post-procedure.
  2. Individuals undergoing catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs.
  3. Individuals who are candidates to have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
  4. At the time of enrollment, the Investigator deems the subject a candidate for same-day discharge (SDD) per standard of care (no procedure related events/complications e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).

Exclusion Criteria

  1. Presence of bruit, palpable aneurysm, significant candida or groin infection.
  2. Prior to closure, presence of hematoma in the accessed limb.
  3. Currently involved in any other clinical trial that may interfere with the outcomes of this study as determined by the Investigator.
  4. Planned use of other closure devices or techniques other than MYNX CONTROL™ VENOUS VCD 6F-12F.
  5. Life expectancy <12 months.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
MCV VCD Treatment

Subjects who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.

The MYNX CONTROLTM VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing 6F to 12F procedural sheaths, with single or multiple access sites in one or both limbs.

MCV VCD is designed to achieve femoral vein hemostasis via delivery of the GRIP TECHNOLOGY™ sealant (an extravascular, water-soluble synthetic hydrogel), using a balloon catheter in conjunction with a standard procedural sheath. The sealant is made of a polyethylene glycol (PEG) material which expands upon contact with subcutaneous fluids to seal the venotomy and is resorbed by the body within 30 days.

The MCV VCD is supplied with a 10ml locking syringe used for balloon inflation and deflation. The catheter shaft has a silicone lubricant to facilitate insertion and withdrawal into compatible sheaths.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Rate of patients with same day discharge (SDD) and without subsequent hospitalization/intervention for access-site complications
Délai: From time of index procedure through end of following day (within 48 hours)

Rate of patients who successfully received a study device at all access sites and had SDD without subsequent hospitalization/intervention for access-site complications either same day post-discharge or the next day

From time of index procedure through end of following day (within 48 hours)
Rate of access-site complications
Délai: From time of study device introduction at first access site through 14 days post-procedure

Rate of access-site complications, assessed per standard of care, through 14 days post-procedure, including:

  • Access Site-Related Hematoma > 6 cm documented by ultrasound
  • Local Access Site Infection confirmed by culture and sensitivity, treated with intramuscular or oral antibiotics
  • Allergic Reaction
  • Access site-related bleeding requiring transfusion, surgical intervention, or rehospitalization
  • Pulmonary embolism requiring surgical or endovascular intervention and/or resulting in death, to be confirmed by CT pulmonary angiography, lung ventilation/perfusion scan (VQ scan), or autopsy
  • Ipsilateral deep vein thrombosis, documented by ultrasound
From time of study device introduction at first access site through 14 days post-procedure

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Time to Ambulation
Délai: From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)

Defined as elapsed time (in hours) between removal of the final MCV VCD and when subject stands and walks 20 feet without evidence of rebleeding from any femoral venous access site.

From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
Time to Discharge
Délai: From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)

Defined as the elapsed time (in minutes) between removal of the final MCV VCD and when the subject is discharged from the hospital, as recorded on the discharge order.

From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)
Time to Hemostasis
Délai: From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)

Defined as elapsed time (in minutes) between removal of each MCV VCD and first observed and confirmed venous hemostasis (per access site analysis).

From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
SDD sustained MCV VCD success
Délai: From end of index procedure through 14 days post-procedure

Defined as the proportion of subjects who did not require hospital intervention within 14 days post-procedure due to access site-related complications

From end of index procedure through 14 days post-procedure
Device success evaluated at the end of the procedure
Délai: End of index procedure

Defined as the ability to deploy the delivery system and deliver the PEG component to achieve hemostasis at each access site

End of index procedure
Procedural Success
Délai: From end of index procedure through 14 days post-procedure

Defined as the attainment of final hemostasis at all venous access sites without major venous access site closure-related complications through 14 days

From end of index procedure through 14 days post-procedure
Procedural Time
Délai: Index procedure

Defined as time of first sheath insertion until the time of removal of final MCV VCD.

Index procedure
Recovery room time
Délai: From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)

Defined as elapsed time (in minutes) between when the subject is transferred to recovery and when the subject is discharged from the hospital, as recorded on the discharge order.

From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)
Analysis of Cost Effectiveness - Comprehensive summary of clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes
Délai: From start time of index procedure through 14 days post-procedure

An analysis of cost effectiveness will be performed based on a summary of key clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes

From start time of index procedure through 14 days post-procedure
Incidence of urinary catheter usage
Délai: From start time of index procedure through end time of index procedure

Number/rate of patients with urinary catheters used during the procedure

From start time of index procedure through end time of index procedure
Incidence of protamine usage
Délai: From start time of index procedure through end time of index procedure

Incidence of protamine usage during the procedure

From start time of index procedure through end time of index procedure
Medication Usage
Délai: From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)

Rate of patients who are administered anti-platelet, anti-coagulant, anti-thrombotic, local anesthetic, protamine or pain medication

From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

24 novembre 2025

Achèvement primaire (Réel)

26 août 2026

Achèvement de l'étude (Réel)

26 août 2026

Dates d'inscription aux études

Première soumission

13 novembre 2025

Première soumission répondant aux critères de contrôle qualité

21 novembre 2025

Première publication (Réel)

24 novembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • P25-8302

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .